BioPharma Resources

NDA 201280 · Boehringer Ingelheim

Tradjenta

Linagliptin · Oral · Dipeptidyl Peptidase 4 Inhibitor

Novel

Last checked: Nov 19, 2026Latest source record: Jun 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

May 2, 2011

Approved uses

8

Original approval plus efficacy supplements

Registered trials

195

53 Phase 3, 5 recruiting

FAERS reports

18,487

13,056 serious, 1,717 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2025.

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . TRADJENTA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ) Limitations of Use • Not recommended in patients with type 1 diabetes mellitus as it would not be effective ( 1 ) • Has not been studied in patients with a history of pancreatitis ( 1 ) Limitations of Use TRADJENTA is not recommended in patients with type 1 diabetes mellitus as it would not be effective. TRADJENTA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRADJENTA [see Warnings and Precautions (5.1) ].

Mechanism: Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TRADJENTA · LINAGLIPTIN 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Linagliptin" as an intervention, any sponsor and status, largest first.

All 195 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,385
  • diarrhoea1,322
  • nausea1,241
  • fatigue1,098
  • dyspnoea1,060
  • off label use1,019
  • dizziness997
  • vomiting976
  • acute kidney injury860
  • malaise843
  • headache810
  • pruritus788

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20102
2011206
2012698
2013589
2014818
20151,202
20161,404
20171,204
20181,281
20191,380
20201,169
20211,238
20221,636
20231,906
20241,457
20251,270
20261,026

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tradjenta (Linagliptin)

2024 spending

$1.13B

Beneficiaries

274,523

1,446,832 claims

Per beneficiary

$4,107

$16.56 per unit

View as table
YearSpending
2020$1,288,663,293
2021$1,318,071,298
2022$1,326,573,079
2023$1,293,567,778
2024$1,127,598,446

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 231 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.